+612 9045 4394
Preventive Pharmacotherapy of Headache Disorders : Frontiers in Headache Research Series - Jes Olesen

Preventive Pharmacotherapy of Headache Disorders

Frontiers in Headache Research Series

By: Jes Olesen (Editor), Stephen D Silberstein (Editor), Peer Tfelt-Hansen (Editor)

Sorry, the book that you are looking for is not available right now.

We did a search for other books with a similar title, however there were no matches. You can try selecting from a similar category, click on the author's name, or use the search box above to find your book.

Share This Book:

Most of the familiar headache drugs are used to stop a headache attack that is already in progress, or about to begin. However, there is now a growing body of research aimed at developing medications that can be taken on a regular basis to prevent headaches from starting. These drugs will be targetted at patients whose headaches are frequent or who get their headaches at predictable times. This book reviews the potential for prophylactic treatment of headache. It provides most of the existing evidence in the field of pharmaco-prophylaxis of migraine and other chronic headaches and may thus, serve as a platform for new initiatives in the field. The book reviews the research into the pharmacological mechanisms involved, the classes of drugs in development and the clinical trials methodology.
The editors have gathered together the leading international experts to produce a book that will appeal to neurologists caring for headache patients, researchers in the field and those based in the pharmaceutical industry.

Section I - Methodology of prophylactic trials 1: Peter J Goadsby: Principles of preventive pharmacotherapy in primary headache 2: Henry J McQuay: Methodology and implementation of systematic reviews 3: Doris Irene Stenver: Adverse events, equally important as efficacy as an outcome parameter? 4: Peer Tfelt-Hansen: Methodology of prophylactic trials: discussion summary Section II - Prophylactic drugs I 5: Peer Tfelt-Hansen: Key issues in the methodology of prophylactic migraine trials 6: M Lanteri-Minet, H Aalchaar, G Besson, F Bille-Turc, F Brudon, A Donnet, J Valance and JL Gastaut: Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France 7: W Hester Visser, William Malbecq, Kim Strohmaier, Christopher Lines and Scott A Reines: Preventive treatment of migraine headache with rofecoxib 8: Achim Frese, Katrin Frese, Sonja Schwaag, Alexandra Rahmann, Ingo-W Husstedt and Stefan Evers: Prophylactic treatment and course of the disease in headache associated with sexual activity 9: Stephen D Silberstein: Propylactic drugs I: discussion summary Section III - Prophylactic drugs II 10: Hans-Christoph Diener and Volker Limmroth: Prevention of migraine: betablockers and amine agonists: efficacy 11: Stephen D Silberstein: Antiepileptic drugs in migraine prevention 12: H Steve White: Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine 13: J Pascual, M Sanchez del Rio, V Mateos, JM Lainez, J Hernandez-Gallego, R Leira and MD Jimenez: Experience with topiramate in patients with refractory migraine 14: Reto M Agosti and Sonja Eugster: Topiramate in a selective group of therapy refractory headache patients 15: Jean Schoenen: Prophylactic drugs II: discussion summary Section IV - Prophylactic Drugs III 16: Lars Bendtsen: Efficacy of antidepressants in headache prophylaxis 17: Elliott Richelson: Antidepressants: mechanisms of action 18: Jean Schoenen, Laura Di Clemente and Gianluca Coppola: Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists 19: Isin Baral Kulaksizoglu, Sibel Cakir and Mustafa Ertas: Treatment of chronic tension type headache with mirtazapine 20: Stewart J Tepper, Marcelo E Bigal, Fred D Sheftell and Alan Rapoport: Botulinum toxin type A in the treatment of refractory headache 21: Sonja Schwaag, Alexandra Rahmann, Achim Frese, Ingo-W Husstedt, Juliane Vollmer-Haase and Stefan Evers: Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection 22: Stephen Silberstein, M Alan Stiles, Cheryl Gebeline-Myers and Kathleen Coughlin Bradley: Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry 23: M Cui and KR Aoki: Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing 24: Gabriella Coloprisco, Sergio De Filippis, Pier Giorgio Santi, Guiseppe Fiore, Anna Rodio and Paolo Martelletti: Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment 25: Yoko Hibi, Hisaka Igarashi, Fumihiko Sakai: Prophylactic treatment of migraine with lomerizine hydrochloride 26: Peter J Goadsby: Prophylactic drugs III: discussion summary Section V - New Targets I 27: Sally Bolton and Celestine O'Shaughnessy: Antagonising peripheral sensitisation in migraine 28: RG Hill, MJ Cumberbatch and DJ Williamson: New possibilities for antimigraine therapy via 5-HT receptors? 29: B Schaerlinger, P Hickel, N Etienne and L Maroteaux: Dihydroergotamine interaction with 5-HT2 receptors and its relevance to migraine 30: Lars Jacob Stovner, Erling Tronvik, Harald Schrader, Grethe Helde, Trond Sand and Gunnar Bovim: Migraine prophylaxis with drugs influencing the angiotensin system 31: Alan M Rapoport, Marcelo E Bigal, Stewart J Tepper, Fred D Sheftell: Naratriptan in the preventive treatment of refractory chronic migraine 32: A Pradalier, M Lanteri-Minet, Ch Lucas and G Geraud: PROMISE study (PROphylaxis of MIgraine with SEglor) 33: M Hamon, S Bourgoin and L Lanfumey: Serotinin receptors and migraine prophylaxis - the case of dihydroergotamine 34: Richard Peatfeld: What is the mechanism of action of ACE inhibitors in migraine prophylaxis? 35: Dominique Valade: Triptans with methysergide 36: Jes Olesen: New Targets I: discussion summary Section VI - new targets II 37: Paul JLM Strijbos and Andrew A Parsons: Nitric oxide and its signalling pathways: a rich source of potential targets for migraine therapy 38: Henri Doods: Calcitonin gene related peptide and migraine 39: Christina Kruuse and Joseph A Beavo: Phosphodiesterases, cyclic nucleotides, and their role in migraine 40: Stefan Evers, Achim Frese, Sonja Schwaag, Reiner Luttmann and Ingo-W Husstedt: The prostaglandin-E1-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia 41: Ray Hill: New targets II: discussion summary

ISBN: 9780198528449
ISBN-10: 0198528442
Series: Frontiers in Headache Research Series : Book 12
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 292
Published: 1st April 2004
Country of Publication: GB
Dimensions (cm): 24.9 x 17.4  x 2.1
Weight (kg): 0.59